Table 5.
Clinical response after 1 year, by therapy
| All therapies | ADA | MTX | TCZ | TOF | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients (n) | 149 | 49 | 23 | 50 | 27 | |||||
| Pretreatment DAS28-ESR | 5.35 (4.40–6.45) | 5.33 (4.34–627) | 4.23 (3.84–5.12) | 5.43 (4.57–6.51) | 6.34 (5.74–7.11) | |||||
| DAS28-defined remission | Y | N | Y | N | Y | N | Y | N | Y | N |
| Patients (n) | 82 | 67 | 26 | 23 | 15 | 8 | 30 | 20 | 11 | 16 |
| Pretreatment DAS28-ESR | 5.00 (4.09–6.13)a | 5.85 (4.90–6.77) | 5.30 (4.06–5.83) | 5.67 (4.82–6.77) | 4.11 (3.75–4.43) | 4.78 (4.24–5.27) | 4.80 (4.23–6.27)b | 6.02 (5.30–7.44) | 6.60 (5.60–7.11) | 6.28 (5.78–7.09) |
| Response rate | 55 % | 53 % | 65 % | 60 % | 41 % | |||||
| Pretreatment 14-3-3η (ng/ml) | 0.50 (0.16–4.95) | 1.05 (0.19–7.75) | 1.16 (0.20–9.06) | 0.47 (0.13–2.14) | 0.70 (0.17–1.89) | 0.42 (0.16–14.55) | 0.23 (0.09–3.03)b | 4.02 (0.46–19.77) | 1.05 (0.30–9.46) | 1.56 (0.20–11.58) |
| 1-yr 14-3-3η (ng/ml) | 0.33 (0.10–1.45) | 0.62 (0.14–3.11) | 0.75 (0.14–2.96) | 0.30 (0.13–1.17) | 0.37 (0.11–0.62) | 0.28 (0.07–18.33) | 0.13 (0.08–0.75)b | 1.52 (0.28–5.57) | 1.24 (0.11–1.85) | 1.27 (0.11–5.08) |
| Pretreatment CRP (mg/ml) | 0.73 (0.15–3.12) | 1.14 (0.26–3.40) | 0.62 (0.14–5.01) | 1.14 (0.40–5.32) | 0.36 (0.06–0.83) | 0.18 (0.08–1.34) | 0.92 (0.14–2.18) | 2.67 (0.40–3.50) | 2.97 (0.56–5.22) | 1.04 (0.33–2.98) |
| 1-yr CRP (mg/ml) | 0.03 (0.01–0.09)b | 0.09 (0.02–0.37) | 0.04 (0.02–0.13)a | 0.14 (0.07–1.22) | 0.05 (0.02–0.13) | 0.12 (0.03–0.31) | 0.01 (0.00–0.030)c | 0.03 (0.01–0.18) | 0.03 (0.02–0.16) | 0.04 (0.03–0.28) |
| EULAR-defined good response | Y | N | Y | N | Y | N | Y | N | Y | N |
| Patients (n) | 101 | 43 | 30 | 19 | 16 | 4 | 40 | 8 | 15 | 12 |
| Pretreatment DAS28-ESR | 5.32 (4.33–6.45) | 5.77 (4.70–6.55) | 5.33 (4.33–6.03) | 5.32 (4.32–6.77) | 4.21 (3.83–5.03) | 4.42 (3.32–5.37) | 5.02 (4.37–6.61) | 5.75 (4.83–6.02) | 6.60 (5.74–7.25) | 6.10 (5.53–6.60) |
| Response rate | 70 % | 61 % | 80 % | 83 % | 56 % | |||||
| Pretreatment 14-3-3η (ng/ml) | 0.62 (0.16–5.02) | 1.48 (0.20–12.72) | 0.61 (0.12–3.61) | 0.70 (0.24–5.84) | 0.65 (0.12–1.03) | 1.05 (0.20–14.82) | 0.37 (0.16–7.33) | 10.34 (0.19– > 20) | 1.05 (0.30–8.16) | 1.56 (0.20–14.02) |
| 1-yr 14-3-3η (ng/ml) | 0.28 (0.10–1.51)b | 0.80 (0.27–5.99) | 0.45 (0.11–1.45) | 0.36 (0.22–1.41) | 0.30 (0.10–0.47)c | 7.39 (0.53– > 18.33) | 0.18 (0.08–2.02)b | 3.42 (0.39– > 20) | 1.24 (0.11–1.85) | 1.35 (0.19–9.06) |
| Pretreatment CRP (mg/ml) | 0.96 (0.21 – 3.35) | 0.64 (0.23 –3.08) | 0.80 (0.27 – 5.33) | 0.68 (0.30 – 4.20) | 0.16 (0.05–0.80) | 0.33 (0.10–1.34) | 1.10 (0.20–3.11) | 0.60 (0.16–2.99) | 2.18 (0.77–4.28) | 1.04 (0.26–3.58) |
| 1-yr CRP (mg/ml) | 0.03 (0.01 – 0.12)c | 0.11 (0.03 – 0.50) | 0.05 (0.02 – 0.14)a | 0.13 (0.07 – 1.50) | 0.04 (0.02–0.24) | 0.13 (0.03–0.22) | 0.01 (0.00–0.05)a | 0.06 (0.02–1.36) | 0.03 (0.02–0.16) | 0.07 (0.02–0.28) |
Abbreviations: ADA adalimumab, CRP C-reactive protein; DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, EULAR European League Against Rheumatism, MTX methotrexate, TCZ tocilizumab, TOF tofacitinib
Values shown are median (interquartile range)
a p < 0.001
b p < 0.01
c p < 0.05